Pacemakers
In the first year, a PPM was implanted in 8.9% of patients. Ten
patients received PPM at 30-day, although it was lower than reported
with the self-expanding CoreValve6, 7 and higher than
reported from the JeneValve registry 16, 26. AR
usually have a larger annulus and lack calcification. These reasons may
have contributed to require a deeper depth of implantation and larger
size of prosthesis. There is some evidence that THV deeper position in
the LVOT is independently associated with a higher PPMI rate and the
larger prosthesis size, valve oversizing is also relevant to risk
factors for pacemakers 30.
Study limitations: Data were obtained in a non-randomized fashion, with
the lack of comparative arms of patients with severe AR treated by
surgery or medical therapy alone. Also, the sample size was relatively
small, and the results were single-center collected, potentially
introducing selection bias.
This single-center study reported the outcomes of TAVR in treating pure
AR. Our results have demonstrated a favorable 1-year survival rate and
symptomatic relieving benefits of TAVR in AR patients.